Our results prove that combination therapy using PD‐1/PD‐L1 inhibitors and RT did not increase the rate of serious AEs (≥grade 3), although rates of mild (grade 1–2) pneumonitis were higher in patients who received combination therapy comprising PD‐1/PD‐L1 inhibitors and RT. The gene discussed is CD274; the disease is pneumonitis.